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adenoma recruits tumor-associated
macrophages by releasing CCL15
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Abstract
Background: The differential diagnosis of follicular thyroid carcinoma (FTC) and follicular adenoma (FA) before
surgery is a clinical challenge. Many efforts have been made but most focusing on tumor cells, while the roles of
tumor associated macrophages (TAMs) remained unclear in FTC. Here we analyzed the differences between TAMs
in FTC and those in FA.
Methods: We first analyzed the density of TAMs by CD68 immunostaining in 59 histologically confirmed FTCs
and 47 FAs. Cytokines produced by FTC and FA were profiled using antibody array, and validated by quantitative
PCR. Chemotaxis of monocyte THP-1 was induced by condition medium of FTC cell lines (FTC133 and WRO82-1)
with and without anti-CCL15 neutralizing antibody. Finally, we analyzed CCL15 protein level in FTC and FA by
immunohistochemistry.
Results: The average density of CD68+ cells was 9.5 ± 5.4/field in FTC, significantly higher than that in FA (4.9 ± 3.4/field,
p < 0.001). Subsequently profiling showed that CCL15 was the most abundant chemokine in FTC compared with FA.
CCL15 mRNA in FTC was 51.4-folds of that in FA. CM of FTC cell lines induced THP-1 cell chemotaxis by 33 ~ 77 %, and
anti-CCL15 neutralizing antibody reduced THP-1 cell migration in a dose-dependent manner. Moreover, we observed
positive CCL15 immunostaining in 67.8 % of FTCs compared with 23.4 % of FAs.
Conclusion: Our study suggested FTC might induce TAMs infiltration by producing CCL15. Measurement of TAMs and
CCL15 in follicular thyroid lesions may be applied clinically to differentiate FTC from FA pre-operation.
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Background
Fine-needle aspiration (FNA) biopsy has been recom-
mended as the most accurate and cost-effective method for
evaluating thyroid nodules [1, 2]. However, its accuracy has
been largely compromised for follicular lesions, namely
follicular thyroid carcinoma (FTC) and follicular adenoma
(FA). The key feature of FTC to distinguish it from FA is
capsular or vesicular invasion, which cannot be detected by
either ultrasound or FNA cytology [3, 4]. Biomarkers for dis-
tinguishing FTC from FA before surgery are much needed.
Tumor associated macrophages (TAMs) play an im-
portant role in tumorigenesis and progression. TAMs
generate an inflammatory environment to trigger or fa-
cilitate tumor initiation, promote tumor cell invasion
and metastasis, stimulate angiogenesis and suppress an-
titumor immunity [5–7]. High density of TAMs was cor-
related with the poor prognosis of a wide range of tumors
such as lung, hepatocellular, colorectal, breast, prostate,
ovarian and thyroid cancers [8–13]. TAMs produced
growth factors (e.g. VEGF, EGF, HGF and bFGF) and che-
mokines (e.g. CXCL12 and IL8) to mediate their oncogen-
esis function [7, 14]. On the other hand, cancer cells
recruit TAMs by releasing colony stimulating factor
(CSF1), granulocyte–monocyte (GM-CSF), transforming
growth factor (TGF) or chemokines (e.g. CCL2) [15, 16].
These factors are potential candidate biomarkers for early
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diagnoses, prognosis evaluation or therapeutic targets of
malignancy.
The first direct evidence of macrophages infiltration in
thyroid cancers was found in 1994 [17]. Subsequent stud-
ies successively suggested positive association between in-
creased TAMs density and thyroid cancer progression
[18–20]. Mice study showed that CSF1/CSF1R mediated
TAMs recruitment in papillary thyroid cancer (PTC) and
targeting CSF1/CSF1R impaired BRAF-induced thyroid
cancer progression [21]. Recently, we reported that TAM
in PTC facilitated tumor metastasis through releasing
CXCL8 and may target CXCR1/2 in tumor cells [22].
However, the roles of TAMs are still largely unknown in
FTC. Noting that the capsular/vascular invasion featured
FTC from FA, and TAMs promote tumor cell invasion,
we proposed TAMs and their associated cytokines should
also feature FTC and may be used as pre-operation bio-
markers to distinguish FTC from FA.
In this study, we first investigated TAMs density in
follicular lesions by using patient samples, and then ex-
plored cytokines responsible for TAMs recruitment and
their roles in differentiating FTC from FA.
Methods
Patients
Paraffin embedded tissue specimens were obtained from
59 patients histologically confirmed as FTC and 47 patients
with FA, and eight fresh-frozen tissue samples (four FTCs
and four FAs) collected from surgical specimens, from
2010 to 2012 at Ruijin Hospital, Shanghai Jiaotong Univer-
sity, School of Medicine. Written informed consents were
obtained from all patients. This study was approved by the
board of medical ethics of Ruijin Hospital.
Cell culture and reagents
FTC133 human cancer cell line was originally from Dr.
Robert Gagel (University of Texas, M. D Anderson Cancer
Center, Houston, Texas), and WRO82-1 cell line was get
from Dr. Zhimin Liu (Chongqing Medical University).
Both of them have been genetically fingerprinted by either
single-nucleotide polymorphism comparative genome
hybridization (SNP-CGH) and verified to be unique [23].
THP-1 cell line was obtained from the American Type
Culture Collection (ATCC, Manassas, VA). Both WRO82-
1 and THP-1 were cultured in RPMI 1640 supplemented
with 10 % heated fetal bovine serum and 1 % LG and 1 %
PS. FTC133 cell line was cultured in DMEM/modified
HAM-F12 medium. All medium were bought from Gibico
(Rockville, MD). The passage numbers of all cell lines
were within 30 passages.
Recombinant human CCL15 was purchased from
Peprotech (rocky hill, USA). Affinity-purified anti-human
CCL15 antibody and normal goat IgG were obtained from
R&D Systems (Minneapolis, USA).
Tissue microarrays and immunohistochemistry
Tissue microarrays (TMAs) were constructed using 2 mm
cores from formalin-fixed, paraffin-embedded tissue blocks.
Immunostaining of CD68 (1:150; Dako, Glostrup,
Denmark), CD163 (1:75; Vector Laboratories, Burlingame,
CA), CD206 (1:5000; Abcam, Cambrige, UK) and CCL15
(1:250; Novus Biologicals, USA) were performed on sec-
tion of 4 μm thickness as previously reported [13]. Briefly,
the first antibody was incubated at 4 °C overnight before
the secondary antibody conjugated with horseradish per-
oxidase was added. DAB (3,3-diami-nopdbenzidine)
substrate was introduced and hematoxylin was used for
counterstaining. The stained sections were microscaned
by nanozoomer2.0-RS (Hamamatsu) to get the photo of
entire sample. A single pathologist, who was blinded to
the histological assessments of each case, counted the
number of CD68/CD163/CD206 positive cells. For tis-
sue microarrays sections, CD68, CD163 or CD206 posi-
tive cells were counted in five independent fields under
400 magnifications (represent 0.06 mm2). For whole tis-
sue sections, CD68+ cells in ten independent fields
under 400 magnifications (represent 0.06 mm2) were
counted. To avoid any overestimation of the number of
TAMs which could have been due to extended cyto-
plasmic ramifications, we counted only cells with a vis-
ible nucleus. The CCL15 staining level was evaluated
by an expert pathologist and was classified as negative
(CCL15-) and positive (CCL15+, ++).
Cytokine antibody array
Surgically resected tissue samples were obtained from
four FTC and two FA patients. RayBio Human Cytokine
Antibody Array G Series was purchased from RayBiotech
(Norcross, GA). According to the manufacturer’s in-
struction, array membranes were incubated for 30 min
in blocking buffer and afterwards in tissue lysates with
120 μg total protein overnight at 4 °C. The membranes
were washed and a diluted cocktail of biotin-conjugated
antibodies was added for 2 h. Membranes were washed
again and the sandwiched antigens were detected by in-
cubation with a fluorescent dye-conjugated streptavidin
solution for 2 h. Signals were captured by laser scanner
Axon GenenPix using Cy3 and analyzed by RayBio
Antibody Array Analysis Tool.
RNA extraction and qRT-PCR
Total RNA was isolated from FTC or FA tissue samples,
and THP-1 cells under different treatments using TRIZOL
reagent (Invitrogen) and 1 mg total RNA was converted
into first-strand cDNA with the First Strand cDNA
Synthesis Kit (Promega, USA) according to the manu-
facturer’s instructions. qRT-PCR was performed in Light
Cycler480 instrument (Roche Diagnostics, Switzerland),
using the SYBR Premix Ex TaqTM (TaKaRa, Japan). The
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expression data were analyzed using △△Ct and ACTB
was used as internal control. Primers used were list in
Additional file 1: Table S5.
Chemotaxis assays
Chemotaxis assays were performed using 8 μm pore size
cell culture inserts within 24-well plates (Corning, USA)
as previously described [22]. FTC133 or WRO82-1 in
exponential phase were cultured with FBS free medium
(plus 0.2 % BSA, Genebase Gene-Tech, China) for 24 h
and then the medium was harvested as condition medium
(CM). THP-1 cells (5 × 105/ml) were seeded into the in-
serts pre-coated with collagen from rat tail (Sigma, USA),
and CM/ mock medium /CCL15 neutralizing antibody
was added in the lower well. After 12 h of incubation, cells
in the upper membrane surface were removed with cotton
swabs. Cells on the lower membrane surface were fixed
with methyl alcohol and stained with 0.1 % crystal violet
(Sigma, USA). The cells of five randomly selected fields
per well were counted using the Axiovert 25 microscope
(Carl Zeiss, Germany) under 400 magnifications. Three
replicate measurements were included in a single
experiment.
Statistical analysis
Statistical analyses were performed by SPSS Version 17.0
and Prism Version 5.0. Data was expressed as mean ±
standard deviation(SD). Mann–Whitney test was used
for continuous variables between groups, while Fisher’s
exact test for counts between categorical variables. All
p values were 2-tailed, and p < 0.05 was accepted as
statistical significance.
Results
TAMs density was increased in FTC compared with FA
We previously found that TAMs increased PTC cancer
progression through CXCL8 [13, 22]. To investigate
whether TAM plays pathologic roles in FTC, we firstly
quantified the amounts of TAMs in follicular thyroid le-
sions. The macrophage marker CD68 was immunostained
in 158 tissue blocks obtained from 106 patients (including
59 FTCs and 47 FAs). We observed CD68 positive cells
unevenly distributed in the lumen of the follicles or inter-
spersed between the tumor cells, but rarely appeared in
non- neoplastic thyroid tissues (Fig. 1). The average
density of CD68+ cells was 9.5 ± 5.4/field in the FTCs,
significantly higher than that in benign thyroid lesions
(4.9 ± 3.4 for FA and 1.3 ± 1.2 for normal thyroid tissue,
Fig. 1 Densities of CD68+ and CD163+ cells in FTCs are significantly higher than those in FAs. Immunohistochemistry analysis of CD68 and CD163 in
158 tissue samples of FTC and FA patients. Normal: adjacent non-neoplastic tissues which exhibit normal pathological phenotypes. Arrows indicate the
CD68+ or CD163+ macrophages. Bar = 20 μm
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p = 1.3 × 10−6 /3.4 × 10−19, Mann–Whitney, Table 1 and
Fig. 1). In order to test whether tissue microarray is
representative of the entire lesion, we further immuno-
stained CD68 in the tissue sections of 20 FTCs and 20
FAs. A total of ten fields under 400X (an area of
300 μm*200 μm) were counted for each sample. The re-
sult showed the same, as significantly higher CD68+
cells in FTC than in FA (7.7 ± 3.7/field versus3.7 ± 1.4/
field, p = 7.3 × 10−5, while on TMAs 10.7 ± 5.3/field
versus 4.2 ± 1.9/field, p = 6.8 × 10−6; Additional file 1:
Table S1 and Additional file 2: Figure S1).
We also compared the immunostaining of CD163 and
CD206, two markers of M2 subgroup of TAMs, in FTCs
and FAs. We found FTC harbored a significantly higher
density of M2 TAMs compared with FA. The number of
CD163+ cells was 6.3 ± 3.9/field in FTC versus 4.6 ± 4.3/
field in FA (Mann–Whitney, p = 0.001, Fig. 1, Table 2);
and CD206+ cells in FTC and FA were 4.3 ± 2.0/field
and 3.0 ± 2.4/field respectively (Mann–Whitney, p =
0.020; Additional file 1: Table S2 and Additional file 2:
Figure S2).
Furthermore, we investigated the relationship between
CD68+ macrophages density and the clinicopathological
features of FTC patients. We found no significant correl-
ation between TAM density and TNM stages, capsular
invasion and vascular invasion (Additional file 1: Table S3).
CCL15 was the most abundant chemokine in FTC
comparing with FA
To discover the specific chemokines that recruit TAM
accumulation in FTC, the abundance of 80 cytokines,
chemokines and growth factors were examined by cyto-
kine antibody array in protein lysis from fresh FTC and
FA tissues. We found that CCL15 was the most abun-
dant chemokine in FTC when compared with FA. We
confirmed this finding by qRT-PCR, which showed
CCL15 mRNA in FTC was 51.4-folds of that in FA
(Fig. 2a). Moreover, the expression of CCR1 (CCL15 re-
ceptor) in monocytes cell line THP-1 can be induced by
condition media of FTC133 cell line (FTC133-CM)
(Fig. 2b) and by recombinant CCL15 (rCCL15) in dose-
dependent and time-dependent manners (Fig. 2c, d).
We tested the mRNA levels of six more genes, including
three with different abundance in antibody array between
FTC and FA, two previously reported TAMs recruiters
(CCL2 and CCL7), and CSF-1 which was reported as
TAMs recruiters in thyroid cancers. However, none of
them exhibited significantly higher expression in FTC
than in FA (Fig. 3).
FTC cancer cells recruited macrophages by secreting CCL15
To confirm that CCL15 directly contributes to macro-
phage recruitment, we performed transwell assay of
monocytes cell line THP-1 by using condition medium of
FTC cell lines WRO82-1 and FTC133. Compared with
mock medium, FTC133-CM and WRO82-1-CM induced
THP-1 cell chemotaxis by 33 and 77 %, respectively
(Fig. 4). Moreover, rCCL15 enhanced THP-1 cell migra-
tion by 97 %. When CM of FTC133 or WRO82-1was
pretreated with anti-CCL15 neutralizing antibody, we
observed reduced THP-1 cell migration in a dose-
dependent manner (35.4 % at 0.1 μg/ml, and 50.2 % at
1 μg/ml for FTC133; 18.9 % at 0.1 μg/ml, and 30.8 % at
1 μg/ml for WRO82-1) (Fig. 4). Collectively, these data
suggested that FTC tumor cell-derived CCL15 played
an important role in recruiting macrophages in FTC.
CCL15 was significantly highly expressed in FTC than in FA
To test whether CCL15 was differentially expressed in
FTC and FA, we compared CCL15 immunostaining in
FTC or FA tissue blocks (Fig. 5). We observed positive
CCL15 immunostaining in 67.8 % of FTCs compared
with 23.4 % of FAs. (Fisher’s exact test, p = 1.4 × 10−5;
Table 3). Interestingly, tumors CCL15 positive expression
also possessed high CD68+ macrophage density, (8.5 ±
5.3/field in CCL15 positive cases versus 6.4 ± 4.8/field in
CCL15 negative cases, p = 0.01, Mann–Whitney test;
Table 3). In consistent with the density of TAMs, no
correlations between CCL15 expression level and clini-
copathological features of FTC patients were observed
(Additional file 1: Table S4).
Discussion
In this study we found FTC produced high level of
CCL15 and recruited higher density of TAMs in FTC
compared to FA. These important characters of FTC may
have clinical significance in differentiating FTC from FA
pre-operation.
The inflammatory microenvironment and macrophages
infiltration have been demonstrated to be correlated with
thyroid cancer progression and prognosis [20]. Our
previous work also indicated that the density of TAMs
was increased in advanced papillary thyroid cancers (PTC).
Table 2 Increased Density of CD163 Positive Macrophages in
FTCs comparing to FAs
Histological Type Case number TAM counts (Mean /field) P value
FTC 59 6.3 ± 3.9
FA 46 4.6 ± 4.3 0.001
Table 1 Increased Density of CD68 Positive Macrophages in
FTCs comparing to FAs
Histological Type Case number TAM counts (Mean /field) P value
FTC 59 9.5 ± 5.4
FA 47 4.9 ± 3.4 1.3 × 10−6
Normal Tissue 55 1.3 ± 1.2 3.4 × 10−19
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However, the role of TAM in FTC remained unclear. In
the current study, we firstly found TAMs was significantly
accumulated in FTC comparing to its benign control.
TAMs can produce chemokines to promote tumor inva-
sion and metastasis [24]. As in PTC, we found TAMs
density was correlated with lymph node metastasis and
advanced tumor stage [13]. However, here we found no
correlations between the density of TAMs and the clinico-
pathological features of FTC patients. The lack of correl-
ation may result from limited sample size, especially those
with advanced TNM stage. Alternatively, different from in
PTC, TAMs might only function in the early phase of FTC
tumorigenesis, independent with tumor progress events.
The underlying mechanism is worth further studies.
Cancer cells recruit TAMs by producing specific che-
mokines, which may be applied clinically as biomarkers
of malignancy. In our study, we confirmed CCL15 pro-
duced by FTC cell was responsible for TAMs recruit-
ment in FTC in vitro. The CC motif chemokine ligand
15 (CCL15) is a potent chemoattractant for leukocytes
and endothelial cells (ECs), and act through a receptor
protein CCR1 [25, 26]. Human colon cancer cells pro-
duced CCL15 to recruit immature myeloid cells (iMCs)
from bone marrow and then promoted tumor invasion
in the invasion front [27, 28]. CCL15 level was associ-
ated with liver metastases in patients with colon cancer
[29]. We also found significant high level of CCL15 in
FTC comparing to FA. However, we failed to observe
correlation between CCL15 expression and tumor stage.
This is consistent with the lack of correlation between
TAMs and FTC clinicopathological features. The influ-
ence of limited sample size was not excluded.
Preoperative diagnosis of FTC (especially minimally
invasive FTC) has been a clinical challenge. In the last
decade, specific molecular biomarkers have been pro-
posed to improve preoperative diagnosis of FTC. These
included immunostaining markers such as galectin-3
combined with CD44v6, p27, cytokeratin19 or HBME1
Fig. 2 CCL15 is highly expressed in FTCs and CCR1 is induced by FTC133-CM. a qRT-PCR analysis of the CCL15 expression level in fresh tissues of
FTC and FA tissues. Relative expression was normalized by the expression of ACTB. Data was presented as mean ± SE (n = 4). b, c, d qRT-PCR analysis
of the CCR1 expression level in Thp-1 cell line. Thp-1 cells were treated with 30 ng/ml PMA or conditional media of FTC133 (FTC133-CM) for 24 h (b);
Thp-1 cells were treated with increasing doses of rCCL15 for 24 h, and 50 μM IFN was used as a positive control (c); Thp-1 cells were treated
with 50 μg/ml rCCL15 for increasing time periods (d). Relative expression was normalized by the expression of CCR1 in Thp-1 under mock
treatment. ACTB was used as internal control and data were presented as mean ± SD (n = 3). Experiments were repeated three times, with
consistent results
Fig. 3 Expression of another 6 candidates in FA and FTC. mRNA levels
of PDGF-BB, IGF-I, IGFBP-2, CSF-1, CCL2 and CCL7 were analyzed by
qRT-PCR in fresh tissues of FTC or FA. Relative expression was calculated
using the expression level of ACTB as internal control and data was
presented as mean ± SE (n = 4)
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Fig. 5 Immunostaining of CCL15 in thyroid follicular lesions. “+” and “-” represents the stage of staining level, which were estimated by pathologist,
who was blind to the histological assessments of each case. Bar = 20 μm
Fig. 4 CCL15 mediates the recruitment of macrophages in FTC. a Transwell assay of Thp-1 cell line by different treatment for 12 h. Bar = 10 μm. b Thp-1 cell
numbers were calculated in each field under 400 magnifications. Both rCCL15 and condition medium of FTC cancer cell lines (FTC133-CM and WRO-CM)
enhanced the recruitment of Thp-1 (*p< 0.05, **p< 0.01, compared with serum-free medium). Anti-CCL15 neutralizing antibody abrogated the recruitment
by FTC133-CM or WRO-CM. (**p< 0.01, ***p< 0.001, compared with condition medium plus isotype-matched IgG). Statistical analysis was performed using a
two-tailed Student’s t-test and the data was presented as mean ± SD (n= 16). Three biological replications were performed, with consistent results
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[3, 30–32]. Moreover, mRNA or miRNA expression pro-
files have identified a group of genes to distinguish FTC
from FA [33–38]. Although these approaches improved
our knowledge on FTC, all of them showed their limita-
tions, such as limited operability or stability in clinical
practice. All the previous efforts have focused on neo-
plasms themselves. The great heterogeneity harbored by
individual tumors hampered the identification of a uni-
versal biomarker to differentiate FTC from FA. Currently,
the golden diagnostic criteria for FTC are capsular inva-
sion or angioinvasion, in which tumor microenvironment
(TME) plays an important role. We proposed that FTC
and FA might harbor different TME and the differences
might have diagnostic values. Indeed, the current study in-
dicated that TAMs, the most important cell component in
TME, specifically accumulated in FTC but not in FA.
More importantly, we identified that CCL15, which re-
cruited TAMs in FTC, was significantly highly expressed
in FTC. To our best knowledge, this is the first study try-
ing to understand FTC and FA in the aspect of TME.
However, the sensitivity and specificity of CCL15 as a
marker to differentiate FTC from FA was not investigated
because of sample limit. Future study should work on
that.
Conclusions
In this study, we found FTC recruited high density of
TAMs by releasing CCL15, which may be applied clinic-
ally to differentiate FTC from FA pre-operation. The
current work revealed the importance role of TAMs in
FTC. Investigation in tumor microenvironment in
addition to tumor cell may bring new insights into not
only the pathogenesis but also early diagnosis of FTC.
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